Fusion Pharmaceuticals (acquired by AstraZeneca)

fusionpharma.com
Innovation Type:
Therapeutics
Cancer Type:
Multiple
Funding Stage:
Exit
Fund:
Compass Rose
Next-generation radiopharmaceuticals for precision medicine (antibody conjugate for lung cancer), providing a safer approach to targeted radiotherapy by helping the drug clear from normal, healthy tissues and reducing toxicity

Related news

FACIT-seeded Fusion Pharmaceuticals acquired for up to US$2.4B by AstraZeneca

FACIT’s portfolio company Fusion Pharmaceuticals is being acquired by AstraZeneca for a total transaction value of up to $2.4 billion. Congratulations to the team at Fusion for building value over the last decade that will have a lasting impact on patients with cancer and the Ontario economy. Read More

FACIT congratulates Fusion Pharma on its Initial Public Offering

June 26, 2020 – FACIT congratulates Hamilton-based Fusion Pharma (NASDAQ: FUSN) on its initial public offering (IPO) with shares of the company beginning to trade on the Nasdaq Global Market exchange today. Read More

FACIT Announces Investment in Fusion Pharmaceuticals and Alpha-Emitting Radiotherapeutics

FACIT's investment will support the development of Fusion’s radiopharmaceutical FPX-01 for the treatment of cancer. Read More

FACIT Features: Fusion Pharma completes $105M Series B financing

April 2, 2019 – Ontario First investor FACIT congratulates portfolio company Fusion Pharmaceuticals, a clinical-stage biotech developing novel targeted alpha radiotherapies... Read More

FACIT Features: Portfolio company Fusion Pharma launches Phase 1 trial for next-gen radiotherapeutic

Fusion Pharma announced the first patient dosing with lead candidate in Phase 1 trial for solid tumors. Read More

FACIT Portfolio Company Fusion Pharmaceuticals Closes US$46M Oversubscribed Series A

FACIT congratulates Fusion on completing the second closing of their Series A, now oversubscribed at US$46M, with new investors joining including Adams Street Partners, Seroba Life Sciences, and Varian Medical Systems Inc. FACIT participated in both, this latest closing and as an early seed investor in Fusion. Read More

FACIT-Seeded Fusion Pharmaceuticals Closes US$25M Series A Led by Johnson & Johnson Innovation

FACIT and OICR report that Fusion Pharmaceuticals Inc. has closed a US$25M Series A financing, with Johnson & Johnson Innovation – JJDC, Inc. as the lead investor. Additionally, new investors include venture groups HealthCap, TPG Biotechnology Partners, and Genesys Capital, as well as founding investor FACIT. Read More

FACIT Features: Fusion Pharma Attracts $20M USD Commitment from Canada Pension Plan Investment Board

January 13, 2020 – The financing enables the company to continue leveraging strong Ontario science, as well as develop manufacturing and local career opportunities for scientists and trainees... Read More

    CONNECT WITH FACIT

    Learn more about how we are driving made-in-Ontario oncology innovations reach the market.